SOUTHEAST USA – Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI), in partnership with Prism Clinical Imaging, Inc., has announced the first successful installation of their combined brain mapping and analysis technology at a large health center system in the southeastern United States State. This collaboration marks a new development in neurosurgical planning and treatment strategies.
The integrated suite of tools from both companies aims to improve the diagnosis and treatment of brain diseases by providing clinicians with advanced imaging solutions. The technologies enable neurosurgeons to precisely navigate to the tumor site, distinguish aggressive tumor tissue from non-tumor tissue, thus facilitating better biopsy and resection planning.
Prism’s expertise in brain mapping software helps identify critical brain structures to avoid during surgery, while IB’s quantitative imaging solutions offer detailed images of brain activity and tumor physiology. The goal of the combined technologies is to enable surgeons to plan the safest and most effective surgical approach, preserving essential functions such as speech and movement, and improving patient prognosis by minimizing postoperative complications.
The importance of this technology is highlighted by the growing demand for diagnostic tools due to the increasing prevalence of neurological disorders. Functional magnetic resonance imaging (fMRI), a component of the technologies provided by IB and Prism, is seeing an increase in use because it is critical to understanding brain activity and planning treatment.
This installation represents the first of its kind for the partnership between Imaging Biometrics and Prism Clinical Imaging, marking a step forward in the application of advanced imaging technologies in healthcare. The companies predict the tools will improve patient care and clinical outcomes in the treatment of brain tumors.
The data for this report is based on a press release.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
